Search results for: FDA
#32455341 2019/07/31 To Up
Identifying outcomes that are important to patients with ocular hypertension or primary open-angle glaucoma: a qualitative interview study.To explore patients' perspectives and experiences living with glaucoma and identify important benefits and risks that patients consider before electing for new glaucoma treatments, such as minimally invasive glaucoma surgical (MIGS) devices.
Jimmy T Le, Kareshma Mohanty, Amanda K Bicket, Michelle E Tarver, Malvina Eydelman, Tianjing Li
2905 related Products with: Identifying outcomes that are important to patients with ocular hypertension or primary open-angle glaucoma: a qualitative interview study.1 kit100 25 100
No related Items
#32454981 2020/05/16 To Up
Current regulatory approaches for accessing potential COVID-19 therapies.This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe to date, the best clinical choice is acquired only after consistent and fair communication and collaboration between licensed clinicians, researchers, regulatory authorities, manufacturers and patients.
Vesa Halimi, Armond Daci, Simona Stojanovska, Irina Panovska-Stavridis, Milena Stevanovic, Venko Filipce, Aleksandra Grozdanova
1515 related Products with: Current regulatory approaches for accessing potential COVID-19 therapies.1 G1.0 mg10 g5 mg 5 G 100ul100μg50 5 G 25 G250 mg
#32454937 2020/05/06 To Up
Zerumbone Promotes Cytotoxicity in Human Malignant Glioblastoma Cells through Reactive Oxygen Species (ROS) Generation.Glioblastoma multiforme (GBM) is the most hostile tumor in the central nervous system. Unfortunately, the prognosis of GBM patients is poor following surgical interventions, chemotherapy, and radiotherapy. Consequently, more efficient and effective treatment options for the treatment of GBM need to be explored. Zerumbone, as a sesquiterpene derived from Smith, has substantial cytotoxic and antiproliferative activities in some types of cancer. Here, we show that exposure of GBM cells (U-87 MG) to Zerumbone demonstrated significant growth inhibition in a concentration-dependent manner. Zerumbone also induced apoptosis and caused cell cycle arrest of human GBM U-87 MG cells in the G2/M phase of the cell cycle. In detail, the apoptotic process triggered by Zerumbone involved the upregulation of proapoptotic Bax and the suppression of antiapoptotic Bcl-2 genes expression as determined by qRT-PCR. Moreover, Zerumbone enhanced the generation of reactive oxygen species (ROS), and N-acetyl cysteine (NAC), as an antioxidant, reversed the ROS-induced cytotoxicity of U-87 MG cells. The Western blot analysis suggested that Zerumbone activated the NF-B p65, which was partly inhibited by NAC treatment. Collectively, our results confirmed that Zerumbone induces cytotoxicity by ROS generation. Thus, the study raises the possibility of Zerumbone as a potential natural agent for treating GBM due to its ability to induce cytotoxicity.
Mohammad Jalili-Nik, Mohammad Montazami Sadeghi, Elmira Mohtashami, Hamid Mollazadeh, Amir R Afshari, Amirhossein Sahebkar
1937 related Products with: Zerumbone Promotes Cytotoxicity in Human Malignant Glioblastoma Cells through Reactive Oxygen Species (ROS) Generation.50ul 100ul 100ul 100ul96T1.00 flask1 mg 100ul50ul10 ug 100ul
Error loading info... Pleas try again later.
#32454391 2020/05/18 To Up
An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells.Since cancer cells have different mitochondrial bioenergetic requirements than non-cancerous cells, therapeutic inhibition of its mitochondrial functionality continues to be an important target for anticancer drug discovery. In this study, a series of acylhydroquinones with different acyl-chain length, and their chlorinated derivatives, in the aromatic ring, synthesized by Fries rearrangement under microwave irradiation, were evaluated for their anticancer activity in two leukemia cell lines. Findings from the primary and secondary screening of the 18 acylhydroquinones, tested at 5 µM on acute promyelocytic leukemia HL-60 and acute lymphoblastic leukemia CEM cells lines, identified an acylchlorohydroquinone (12) with a highly selective anti-proliferative effect toward HL-60 cells. This compound induced S-phase arrest in the cell cycle progression of HL-60 cells with insignificant toxicity on leukemic CEM cells and non-cancerous Hs27 cells. In HL-60 leukemic cells, 12 triggered increased mitochondrial NADH oxidation, increased respiration in presence of oligomycin (state 4o), mitochondrial depolarization, and ROS production, suggesting an uncoupling of OXPHOS. This provoked a metabolic adaptation dependent on AMPK/ACC/autophagy axis, having the mitochondrial β-oxidation a pro-survival role since the combination of 12 and etomoxir, a carnitine palmitoyl-transferase (CPT) inhibitor promoted extensive HL-60 cell death. Finally, 12-induced metabolic stress sensitized to HL-60 cells to cell death by the FDA-approved anti-leukemic drug ABT-199, a BH3 mimetic. Therefore, our results suggest that acylchlorohydroquinone is a promising scaffold in anti-promyelocytic leukemia drug research.
Viviana Donoso-Bustamante, Edgar A Borrego, Yareli Schiaffino-Bustamante, Denisse A Gutiérrez, Juan Pablo Millas-Vargas, Sebastián Fuentes-Retamal, Pablo Correa, Ileana Carrillo, Renato J Aguilera, Dante Miranda, Ignacio Chávez-Báez, Rodrigo Pulgar, Félix A Urra, Armando Varela-Ramírez, Ramiro Araya-Maturana
1629 related Products with: An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells.100 100 μg100 μg100 μg1 mg100 μg100 μg100ug Lyophilized100 μg100 μg100 μg
#32454098 2020/05/23 To Up
Prurigo Nodularis: Epidemiology and Clinical Features.Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk. In addition to its significant impact on quality of life, many patients with PN are recalcitrant to therapy as there are currently no FDA approved therapies. In the first article of this 2-part continuing medical education series, we describe the broader epidemiology, patient demographics, physical exam findings, and symptoms to aid in the timely recognition and diagnosis of PN. Furthermore, we quantify the burden of comorbidities in PN by discussing the broad spectrum of systemic diseases and mental health conditions that have been associated with this condition. The second article of this 2-part series will focus on the pathogenesis of PN and provide detailed algorithms for comprehensive work-up and management.
Amy H Huang, Kyle A Williams, Shawn G Kwatra1,000 tests100ulML
#32454050 2020/05/23 To Up
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.Hyperkinetic movement disorders comprise a variety of conditions characterized by involuntary movements, which include but are not limited to tardive dyskinesia, chorea associated with Huntington's Disease, and tic disorders. The class of medications that have been used to treat these conditions includes Vesicular Monoamine Transporter-2 (VMAT2) inhibitors. In 2008, the FDA approved tetrabenazine as a treatment for chorea associated with Huntington's Disease. Optimization of the pharmacology of tetrabenazine has since led to the approval of two new VMAT2 inhibitors, deutetrabenazine and valbenazine. The objective of this review is to provide background on the role of VMAT in monoamine neurotransmission, the mechanism of VMAT2 inhibition on the treatment of hyperkinetic disorders (specifically tardive dyskinesia and chorea associated with Huntington's Disease), the pharmacology and pharmacokinetics of the commercially available VMAT2 inhibitors, and a summary of the clinical data to support application of these medications.
Jessa Koch, Wei-Xing Shi, Khashayar Dashtipour 100 G0.25 mg1010mg50 ml50 mL1 g 1 G 2x5L
#32453592 2020/05/26 To Up
Acidic pH-Induced Modification of Energy Transfer in Diatom Fucoxanthin Chlorophyll -Binding Proteins.pH influences excitation-energy-relaxation processes in photosynthetic light-harvesting complexes. Here we report the excitation-energy dynamics by pH changes in fucoxanthin chlorophyll a/c-binding proteins (FCPs) isolated from a diatom Phaeodactylum tricornutum, probed by time-resolved fluorescence spectroscopy at 77 K. Fluorescence curve measured at pH 5.0 showed a shorter lifetime component than that measured at pH 6.5 and 8.0. The rapid decay component at pH 5.0 is supported by fluorescence decay-associated (FDA) spectra, where strong fluorescence decays relative to fluorescence rises appear in the pH-5.0 FDA spectrum with 70 ps. These results indicate that the diatom FCPs switch their function from light-harvesting to energy-quenching via arrangements of the energy-transfer pathways under acidic pHs. Based on the crystal structure of the diatom FCPs, we propose a model for the energy-quenching machinery through structural changes of the pigment environments, thus providing insights into the pH-dependent light-harvesting strategy in the diatom FCPs.
Ryo Nagao, Makio Yokono, Yoshifumi Ueno, Jian-Ren Shen, Seiji Akimoto
2662 related Products with: Acidic pH-Induced Modification of Energy Transfer in Diatom Fucoxanthin Chlorophyll -Binding Proteins.1 mg10100.00 ug50 50101mg100 ul1001mg10 1mg
Error loading info... Pleas try again later.
#32453306 2020/05/19 To Up
Chronopharmacokinetics and Food-Effects of Single-Dose LCP-tacrolimus in Healthy Volunteers.A modified-release version of tacrolimus, LCP-tacrolimus (LCPT; Envarsus XR, Veloxis Pharmaceuticals), has been licensed in the United States for prophylaxis of organ rejection in de novo kidney transplant patients. As tacrolimus has a narrow therapeutic window, the impact of circadian patterns on LCPT drug exposure, including food and chronopharmacokinetic effects, needs to be elucidated to optimize dosing.
Rita R Alloway, Jennifer Trofe-Clark, Daniel C Brennan, Janice Kerr, Elizabeth A Cohen, Ulf Meier-Kriesche, Daniel R Stevens, Misbah A Moten, Jeremiah D Momper
2079 related Products with: Chronopharmacokinetics and Food-Effects of Single-Dose LCP-tacrolimus in Healthy Volunteers.96 wells2100 μg1 mg100 ul (2 mM)100ug100ug25 mg100ug2 Pieces/Box
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia